ImmunoGen, Inc.·4

Dec 27, 5:13 PM ET

Berkenblit Anna 4

4 · ImmunoGen, Inc. · Filed Dec 27, 2022

Insider Transaction Report

Form 4
Period: 2022-05-20
Berkenblit Anna
VP & Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-11-14+222,300333,450 total
    Exercise: $4.55From: 2022-11-14Exp: 2030-02-07Common Stock (222,300 underlying)
  • Award

    Stock Option (Right to Buy)

    2022-05-20+111,150111,150 total
    Exercise: $4.55From: 2022-05-20Exp: 2030-02-07Common Stock (111,150 underlying)
Footnotes (2)
  • [F1]On February 7, 2020, the reporting person was granted an option to purchase 444,600 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
  • [F2]On February 7, 2020, the reporting person was granted an option to purchase 444,600 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.

Documents

1 file
  • 4
    form4-12272022_101256.xmlPrimary